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To identify a receptor binding site of human inter- 
leukin-6  (IL-6),  we created a library of IL-6  variants 
with single amino acid substitutions in the last 15 
residues (171-186) in the COOH terminus of IL-6. 
Twenty-seven  IL-6  variants  were tested for biological 
activity on  a  human hepatoma and a mouse hybridoma 
cell line. Most variants  were additionally tested in a 
receptor binding assay using a human myeloma cell 
line. Several single amino acid substitutions in the 
COOH terminus of IL-6  were found to decrease biolog- 
ical activity significantly. This is especially seen in 
variants  with amino acid substitutions that alter  the 
postulated amphipathical a-helix structure between 
residues 178 and 183. The two  highly conserved Arg 
residues at positions 180 and 183 seem to play a very 
important role in biological activity. The loss  of biolog- 
ical  activity  in  all  inactive  variants is completely par- 
alleled  by a decrease of  IL-6 receptor binding, as de- 
termined by competition binding experiments. One  mu- 
tant (Leu171) displayed a higher activity on human cells 
and a higher binding affinity  to  the receptor and can 
be considered an  IL-6  agonist. It is concluded that the 
amphipathical a-helix structure in the COOH terminus 
of IL-6 is critical for ligand receptor interaction. Fur- 
thermore, the region between residues Serl” and 
ArglS3  (Ser-Leu-Arg-Ala-X-Arg) is identified as a 
receptor binding site in the COOH terminus of human 
IL-6. 
Interleukin-6 (IL-6)’ is a  multifunctional cytokine that is 
produced by a variety of cells such as B-cells, T-cells, mono- 
cytes, fibroblasts, and endothelial cells (f6r review  see  Refs. 
1, 2, and 3).  IL-6  exerts several activities including terminal 
differentiation of B-cells (4), proliferation and differentiation 
of T-cells (5), regulation of the acute  phase response (6),  and 
growth regulation of epithelial cells (7). It also stimulates the 
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differentiation of hematopoietic progenitor cells alone or in 
combination with other cytokines such as  IL-3  and IL-4 (8, 
9). IL-6 also plays a role in the differentiation of megakaryo- 
cytes and seems to be the most important factor for throm- 
bopoiesis (10). Another important feature of IL-6 is the ability 
to act as a growth factor of precancerous cells, such as in 
myeloma and plasmacytoma (11,12). In accordance with these 
properties, the  target cells for IL-6 include B-cells, T-cells, 
myeloma cells, megakaryocytes, monocytes, early stem cells, 
and hepatocytes. 
The various biological effects of IL-6 on the different cell 
types  are  initiated by the interaction of IL-6 with two distinct 
receptor subunits.  First,  IL-6 will form a complex with an 80- 
kDa receptor followed by the binding of this complex to a 
non-ligand binding subunit, the membrane glycoprotein 
gp130 (13, 14). The binding of the IL-6-80-kDa receptor 
complex to gp130 results in signal transduction (14). The 
signal transduction  pathways upon IL-6 receptor binding are 
still unclear; however, it  has been recently demonstrated that 
the biological effect of IL-6 on B-cell hybridoma cells is 
mediated by a novel protein  kinase signaling pathway result- 
ing in the activation of JunB  and  TIS11 gene transcription 
(15). 
In  the absence of a tertiary  structure of IL-6, the ligand- 
receptor model for IL-6 is based on the homology with other 
proteins. Bazan (16) has extensively analyzed the homology 
of various evolutionarily related  proteins by means of com- 
puter modeling and indicated that a  amphipathical  a-helical 
structure is found  in the COOH terminus of several cytokines 
including IL-6, erythropoietin, myelomonocytic growth factor, 
granulocyte-colony stimulating factor (G-CSF), as well as 
growth hormone and prolactin.  Structure-function  studies  on 
growth hormone, G-CSF, and  IL-3 suggest that  this amphi- 
pathic &-helix structure  at  the COOH termini of these pro- 
teins is involved in receptor binding (17-19). 
Several studies on IL-6 have indicated that the COOH 
terminus of IL-6 is important for biological activity. Braken- 
hoff et al. (20) showed by epitope mapping that neutralizing 
monoclonal antibodies  against  IL-6 were directed against  a 
region in the COOH terminus of IL-6, suggesting a role of the 
COOH terminus  in biological activity. More direct evidence 
for the importance of the COOH terminus was obtained by 
structure-function  analysis of IL-6. Two studies showed that 
IL-6 variants  with deletions of the COOH-terminal 52 or 20 
amino acids do not have any detectable IL-6 activity on 
human and mouse cell lines (20,21). Kriittgen et al. (22) found 
that even a deletion of only the last three amino acids of IL- 
6  results  in  a significant loss of biological activity. None of 
these  IL-6 variants was, however, tested  for binding to the 
IL-6 receptor. Therefore, it remains unclear whether the loss 
of activity is due to a loss of receptor binding or to a defective 
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signal  transduction  upon  IL-6 receptor interaction. 
This led us to investigate the exact role of the COOH 
terminus of IL-6 for biological activity as well as receptor 
binding. Specifically we have  attempted  to identify the  indi- 
vidual residues involved in receptor binding. We created a 
library of IL-6  variants  with single amino acid substitutions 
in the COOH terminus using saturation mutagenesis. We 
found  that single amino acid changes  in  the COOH terminus 
of IL-6  can completely  abolish biological activity  and  receptor 
binding. I t  is concluded that  the  receptor  binding  site of the 
COOH  terminus of IL-6  is located  between the residues Ser17' 
and ArglR3. 
EXPERIMENTAL  PROCEDURES 
Construction of Recombinant ZL-6 
The construction of the wild-type IL-6 gene has been described 
previously  (21). Briefly an  IL-6 gene containing 4 serines  instead of 
the naturally occurring  4 cysteines was constructed from 22 synthetic 
oligonucleotides and cloned into a modified pBS M13+ cloning  vector 
(Stratagene, La Jolla, CA). By replacing an EcoRV-StuI fragment 
with a fragment assembled from 6 oligonucleotides containing four 
codons corresponding to  the four cysteines  in  natural IL-6, the wild- 
type IL-6 gene was constructed. This gene  was  cloned into the 
expression  vector p340. This vector is used  for  high level expression 
of an IL-6-@-galactosidase  fusion protein  with a small collagen linker 
between  the two proteins. The construction of the expression  vector 
has been previously reported (23). A synthetic minicistron was in- 
serted downstream of the promoter to increase levels of protein 
expression  (23).  The expression  vector containing wild-type IL-6  is 
called p478. 
Construction of ZL-6 Mutants 
A  library of point  mutations  in  the COOH terminus of IL-6 was 
made by saturation mutagenesis, as described earlier (24). In this 
method, two complementary oligonucleotides are synthesized that 
cover  the region to  be investigated. By contaminating  the  phosphor- 
amidites with  a small  amount of each of the  other  three  phosphor- 
amidites  during  synthesis of the oligonucleotide, an oligonucleotide 
is  obtained  that  has several mutations  in  its sequence compared  to 
the wild-type gene to be studied. 
To reduce the background of nonmutated IL-6 in subsequent 
cloning procedures a BglII-PmlI fragment of the p478 vector was 
replaced by a  29-bp segment  constructed from  two oligonucleotides. 
The oligonucleotides (a = GAT CTT AAG TAG TAG GTA CCA 
A G C T T C A C a n d b = A A T T C A T C A T C C A T G G T T C G A A G  
TG) were made on a DNA synthesizer (Applied Biosystems 380A, 
Foster City, CA) and purified by reverse-phase high performance 
liquid chromatography.  Reagents were obtained from  American  Bio- 
netics  (Hayward, CA). By inserting  this  fragment  the @-galactosidase 
gene  is  out of frame with the  initiating  methionine.  This vector  (p560) 
was used for further cloning experiments. 
Four oligonucleotides c, d, e,  and f that  replaced the  BglII-PmlI 
segment of the original  expression  vector  p478 were synthesized. This 
segment  contains  the  last 46 bases of the  IL-6 gene and  part of the 
collagen linker of the fusion protein.  The comulete seauence of these 
oligonucleotides is: c = GAT CTT 
TGG CCC AAG AGG TCT CGC TGG CCC ACA AGG TCC AC; e 
= GTG GAC CTT  GTG GGC CAG CGA GAC CTC  TTG GGC CAA 
A A G C A C C A G C A G G A C C A A C A G G A C C : f = A A C A G G A C C  
A G G A T C T G A C A T T T G C C G A A G A G C T C T C A G G C T A G A  
CTG CAG GAA CTC CTT AAA A. The  nonunderlined  part of the 
oligonucleotides c and f as well as  the complete oligonucleotides d 
and e are identical to  the original segments  in  the expression  vector 
p478. The  underlined  part of the oligonucleotides code for the  COOH- 
terminal 46 bases of the  IL-6 gene, which was  mutagenized by using 
a mixture of phophoramidites  in  the  synthesis mixes during  synthesis 
of the oligonucleotides. The synthesis mixtures contained 96% of 
pure nucleotide and a 4% equimolar  mixture of all phosphoramidites. 
I t  was calculated that  about 20% of the  IL-6  constructs  should be 
wild-type IL-6 and 80% should have single or multiple mutations 
(24). A 129 bp fragment was obtained by ligating the  pairs of oligo- 
nucleotides d-f and c-e. The  fragment was cloned into p560, which 
resulted  in an expression  vector  with the complete  IL-6-P-galactosid- 
ase fusion protein  that  has several point  mutations  in  the COOH- 
terminal  part of IL-6.  After transformation of XL-1 Blue  cells (Stra- 
tagene,  La  Jolla, CA), the  transformation  mixture was plated  out  on 
Luria  broth  culture  plates,  coated with  ampicillin and  tetracyclin  as 
selection markers and isopropyl-@-D-thiogalactopyranoside (IPTG) 
for induction of fusion protein synthesis and 5-bromo-4-chloro-3- 
indolyl (3-D-galactopyranoside (BCIG)  as a substrate for @-galactosid- 
ase  to be able to select  for dark blue colonies. This  first  transformation 
resulted  in mixed  colonies  because the  complementary oligonucleo- 
tides c and f are likely to have different sequences due to the 
mutagenesis procedure. The colonies were washed off the  plates  and 
DNA was purified and used  for  a  consecutive transformation  to  obtain 
pure colonies. A total of 250 blue  colonies were checked for having 
the 129-bp insert by the polymerase chain reaction (PCR) (25). The 
plasmids  that  had  the  correct size insert were used for further  analy- 
sis. Unfortunately  this  mutagenesis procedure created  IL-6  variants 
with  single amino acid substitutions in 14 of the  last  15 residues of 
IL-6. Therefore  an  additional  variant was made using site-directed 
mutagenesis. This variant (Arg'" to Lys) was made using the  T7- 
GENTM  Mutagenesis  kit (U. S. Biochemicals,  Cleveland, OH) accord- 
ing  to  instructions provided by the  kit  (26). Because we wanted  to 
have  a non-conservative replacement of residue Glu'", a mutant was 
made by oligonucleotide-directed mutagenesis of one of the  obtained 
double-point  mutants ( G ~ u ' ~ ~  to Val and ArglS3 to  Lys) using PCR. 
One of the oligonucleotides was annealed over the  last 24 bases of 
the coding  sequence of IL-6,  thereby  changing  these  last bases to  the 
original IL-6 coding  sequence and  the LyslR3 to  the original  residue 
(Arg). After  ligation of the  PCR  product  in  the vector, an  IL-6  variant 
with only G ~ u ' ~ ~  replaced by Val was created. 
Expression,  Purification, and  Quantitation of Recombinant ZL-6 
Variants 
Detailed description of our  bacterial expression  system has previ- 
ously been published (21, 23, 26). Briefly, the expression vectors 
containing  the gene for the fusion protein with IL-6  mutants were 
transformed in Escherichia coli JM101. Single ampicillin-resistant 
colonies were picked to  inoculate  10-ml  broth  cultures. At log phase 
growth of the  bacteria, expression of the fusion protein was induced 
by addition of 100 ml of IPTG  (25  mg/ml). @-Galactosidase  activity 
was measured and at  maximum levels of activity, bacteria were 
pelleted by centrifugation and stored at -20 "C until further use. 
Bacteria were resuspended in 1 ml of 0.5 X phosphate-buffered saline 
and lysed by repeated freezing and  thawing  after lysozyme treatment. 
T o  reduce  viscosity, the  lysate was sonicated  and  the fusion protein 
was pelleted by centrifugation. The pellet was washed to remove 
soluble contaminants  and  the fusion protein was solubilized in 2% 
sodium lauroyl sarcosine. Insoluble contaminants were removed by 
centrifugation  and  the fusion protein was precipitated by two rounds 
of selective ammonium sulfate precipition. The  IL-6  variants were 
cleaved from  the p-galactosidase by collagenase treatment  prior  to 
quantitation  or use in bioassays.  Because of the high amounts of IL- 
6  expressed in  the induced bacteria, we were able to  quantitate  the 
protein  preparations by denaturing sodium dodecyl sulfate-polyacryl- 
amide gel electrophoresis under reducing conditions followed by Coo- 
massie staining  and  scanning  laser  densitometry. 
Bioassays 
Hybridoma Growth Assay-The hybridoma  growth factor  activity 
was measured using  an  IL-6-dependent, mouse-mouse  hybrid cell line 
(7TD1) as described previously (27). Briefly, 7TD1 cells were sus- 
pended a t  a density of 2 X lo4 cells/ml in Iscove's-DMEM  medium 
containing  10%  fetal bovine serum, L-arginine  (0.55 mM), L-aspara- 
gine (0.24 mM), L-glutamine (1.5 mM), P-mercaptoethanol  (50 mM), 
hypoxanthine (0.1 mM), thymidine (16 mM), and  penicillin/strepto- 
mycin. Cells were plated in 96-well tissue culture plates (100 ml/ 
well). IL-6  samples  to be tested were diluted into  the  same medium, 
and each dilution was tested by adding 100 ml/well to the plated 
cells. After  4 or 5 days, the  number of cells  was evaluated by colori- 
metric  determination of the hexosaminidase levels (28). Plates were 
read a t  a wavelength of 405 nm on a Vmax ELISA plate reader 
(Molecular Devices Corp., Palo Alto, CA). 
Hepatocyte Stimulation Assay-Hepatocyte stimulation activity 
was measured  using  a human  hepatoma cell line  HEP3B2.  The cells 
were maintained  in  DMEM-H medium supplemented with 10% fetal 
bovine serum  and penicillin/streptomycin. On the  day before treat- 
ment cells were trypsinized  and  plated  on 96-well tissue  culture  plates 
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at a density sufficient to give confluent monolayers after overnight 
growth. The next day, the IL-6 samples to be tested were diluted in 
maintenance medium supplemented with M dexamethasone, and 
each dilution was tested  in duplicate by adding 100  ml/well to  the 
plated cells. Conditioned medium  was collected after 48 h and assayed 
for fibrinogen production by a sandwich ELISA using a commercially 
available capture antibody (IgG fraction, goat anti-human fibrinogen; 
Cappel, Durham, NC) and a peroxidase-conjugated detection anti- 
body (peroxidase conjugated IgG fraction, goat anti-human fibrino- 
gen; Cappel). Color  was  developed using a peroxidase substrate  (Kir- 
kegaard & Perry, Gaithersburg, MD) and plates were read at  a 
wavelength of  450 nm on the Vmnx plate reader. 
Calculations 
All assays were carried out in duplicate serial dilutions of three or 
more independent preparations of each IL-6  variant. The biological 
activities were determined from dose-response curves prepared for 
each protein preparation. To minimize variation in  these biological 
assays a duplicate protein preparation of wild-type IL-6 was used on 
each 96-well tissue culture plate to calculate the activity of two 
(HEP3B2) or three (7TD1) IL-6 variants on the same plate as a 
percentage of wild-type IL-6. For the  7TD1 assay ODlos was assumed 
to be directly proportional to  the cell number and was plotted directly 
against the log  of the IL-6 concentration. For the HEP3B2 assay the 
OD450 was converted to fibrinogen concentration using the V, plate 
reader software before being plotted. For each assay the roughly 
linear portion of each dose-response curve was fitted with a second 
order polynomial curve using a computer program. The IL-6 concen- 
tration  that gave half-maximal proliferation in the 7TD1 assay was 
calculated for each mutant, and this value was used to calculate 
hybridoma growth activity relative to the wild-type recombinant IL- 
6. For the HEP3R2 assay, the IL-6  concentration causing a doubling 
of fibrinogen secretion was calculated, since this value allowed a more 
accurate comparison of biological activities, especially for the rela- 
tively inactive mutants. The activity of each IL-6 mutant was calcu- 
lated by taking the mean (and  standard error of the mean) of the 
activities determined for the independent protein preparations. 
3 i n ~ i ~  Assays 
Binding competition studies were performed using human recom- 
binant IL-6 derived from E. coli (generously provided by Dr. Steve 
Clark, Genetics Instititute, Cambridge, MA). IL-6 was radioiodinated 
using the  Bolton-Hunter reagent (Du  Pont-New England Nuclear) 
as was described in detail earlier (29). The specific activity of the 
radiolabeled IL-6 was 22 mCi/gg. For the binding experiments we 
used a  human myeloma cell line U-266. These cells were  grown in 
RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 
mM L-glutamine, and penicillin/streptomycin. This medium  was also 
used for making the dilutions of the IL-6  variants and as binding 
medium. The fetal bovine serum batches were routinely tested for IL- 
6 activity and only batches that showed  negligible IL-6 activity were 
used for competition binding experiments. Cells were harvested by 
low speed centrifugation, washed once in Ca*+/Mg'-free phosphate- 
buffered saline and resuspended at  a concentration of IO' celIs/mi 
medium of 4 "C. The IL-6 variants were treated with collagenase and 
diluted immediately afterward to  the desired concentrations in bind- 
ing medium. '251-IL-6 was diluted to a concentration of 16 ng/ml. 
Thereafter 100 p1 of cells, 50 gl of IL-6  variants,  and 50 p1 of Iz5I-IL- 
6 were transferred in rapid succession using a 12-well multichannel 
pipet into round-bottomed, polyvinyl 96-well plates (Dynatech,  Chan- 
tilly, VA) to yield a final concentration of lo6 cells/200 pl, 0.2 nM 
labeled 1L-6 and varying concentrations of IL-6 variants (ranging 
from 1600 to 0.194 ng/200 pl). Binding was done by sealing the plates 
with acetate plate sealers (ICN Biomedicals, Costa Mesa, CA) and 
end-over rotation for 3 h at 4 "C.  Thereafter, cells were quickly 
pelleted by spinning the plates in a Beckman TJ-6 table-top  centri- 
fuge (Beckman Instruments, Fullerton, CA). The  supernatants were 
aspirated using a 12-channel aspiration/washing device (Immuno 
Wash 12, Nunc, Denmark). The cell pellets were washed once with 
200 pl  of ice-cold  Ca"/Mg+-free Hank's balanced salt solution, resus- 
pended in 200 p1 of Hank's balanced salt solution, transferred to 
scintillation vials, and counted in a gamma counter. 
Data for Scatchard analysis and  the competition binding experi- 
ments were obtained by measuring the binding in the presence of a 
constant concentration of '""I-IL-6 and varying concentrations of 
unlabeled IL-6 variants. The results of the Scatchard and competition 
binding studies were analyzed using the nonlinear curve fitting pro- 
gram LIGAND (30). After the Kd of wild-type IL-6 and  the IL-6 
variants for the receptor were calculated, we expressed the receptor 
binding capacity of the IL-6 variants as a percentage of receptor 
binding of wild-type human  IL-6 by calculating the quotient of Kd 
wild-type IL-6/& variant IL-6. This allowed us to compare the 
binding capacity of the IL-6  variants with the biological activity of 
the variants on human cell lines which was also expressed as a 
percentage of wild-type IL-6. For several mutants that competed 
poorly with wild-type IL-6 for the receptor binding sites, even using 
very  high concentrations of the  mutant proteins, we could not calcu- 
late a Kd. Using the EBDA/LIGAND program we were able to 
calculate an apparent IC, that was used to estimate the residual 
receptor binding capacity of these  variants (in most of these  variants 
<2% of wild-type IL-6). 
RESULTS 
C o ~ t r ~ c ~ i o ~  of the IL-6 Variants-For the studies de- 
scribed here we have used a previously constructed vector 
(~478)  for high level expression of an IL-6-/3-galactosidase 
fusion protein. This vector allows us  to produce large quan- 
tities of IL-6 variants  in IO-ml cultures (21,  26). To obtain a 
large number of IL-6 variants with  different mutations in the 
COOH terminus, we used the  saturation mutagenesis tech- 
nique (24). First we made some alterations in  our expression 
vector p478 to reduce the background after cloning. Afterward 
a library was constructed by cloning a 129-bp fragment com- 
posed of two pairs of annealed oligonucleotides into this 
altered vector. Two of these oligonucleotides coding for the 
15 COOH-terminal amino acids of IL-6 contained several 
mutations compared to  the original IL-6 gene. These  muta- 
tions were introduced during oligonucleotide synthesis by 
contaminating the synthesis mixes with the  other three phos- 
phoramidites. After ligation of the fragment into  the expres- 
sion vector and two consecutive transformations, numerous 
blue colonies were obtained. A total of 250 colonies were 
screened using PCR  for having the correct  insert. Afterward 
201 plasmids were further analyzed by dideoxy sequencing. 
Wild-type IL-6 was found in 50 (25%) of the clones, 68 (34%) 
had one amino acid substitution and  83  (42%) showed two or 
more amino acid changes. Repeated  mutations were found in 
24%  of the  mutated clones and 30% of the  IL-6  variants were 
not useable for further analysis because of deletions or inser- 
tions, the introduction of stop codons or the loss of collagenase 
cleavage sites. We obtained 63 unique variants of which 32 
had  a single amino acid substitution and 31  had two or more 
substitutions  in the COOH terminus of IL-6. We selected IL- 
6 variants with the most interesting single amino acid muta- 
tions for further analysis of the biological activity compared 
to  re~ombinant IL-6. In addition we made two other IL-6 
variants by site-directed mutagenesis to cover all 15 COOH- 
terminal amino acids of IL-6. All IL-6 variants  are shown in 
Fig. 1. The  variants with two or more amino acid substitutions 
were not used for further analysis. 
Biological  Activity of the IL-6 Variants-After expressing 
the proteins in our high level bacterial expression system, we 
performed two assays with human and mouse cell lines to 
determine the biological activity of our IL-6 mutants:  a  fibrin- 
ogen induction assay using the human hepatoma cell line 
HEP3B2 and a hybridoma proliferation assay using an IL-6 
dependent  murine hybridoma cell line 7TD1. The results of 
both  assays are summarized in  Table I. The biological activi- 
ties of all variants  are shown as a percentage of the activity 
of wild-type recombinant IL-6, which has been defined at  
100% for both assays. 
As is shown in  Table I,  the biological activity of IL-6  can 
be significantly altered by substituting single amino acids in 
the COOH-terminal region. Replacement of the ArglBo and 
Arg'83 results in a complete loss of activity. Interestingly,  not 
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FIG. 1. Single amino  acid  substitutions made in the COOH 
terminus of IL-6 using saturation mutagenesis. The top and 
bottom  line give the sequence of the  last 15 residues of human IL-6. 
Two  IL-6  variants  that were constructed  using  site-directed  mutagen- 
esis  are labeled  with an asterisk. For  details  on  construction of the 
library, see “Experimental Procedures.” 
TABLE I 
Biological activity of the IL-6 uariants on  human and mouse cell lines 
Biological activity of the IL-6 variants expressed in percent of 
wild-type recombinant IL-6, that has been defined as 100%. The 
mean  and S.E. are given of at least  three  different  protein  prepara- 
tions. The biological activity of the IL-6 variants was tested on a 
human hepatoma cell line (HEP3B2) and a mouse hybridoma cell 
line (7TD1). The  mutants  are listed as x > y, where n is the original 
amino acid at   the specific position in wild-type human  IL-6  and y the 
amino acid substitution.  For  details on the  activity  assays see “Ex- 
Derimental  Procedures.” 
Position  Residue > substitution HEP3B2 
Hepatoma cell line  Hybridoma cell line 
mean f S.E. (%) mean ? S.E. (%) 
7TD1 
171 Phe > Cys 
171 Phe > Leu 
48 * 6 54 f 8 
172 
153 + 13 
Lys > Gln 
92 * 11 
54 f 11 72 * 0.9 
173 
173 
Glu > Asp 83 f 9 68 f 0.4 
Glu >Val 
174 
72 * 10 17 f 1 
Phe > Val 
174 
66 k 15 61 * 4 
Phe > His 46 f 6 
175 
98 f 4 
Leu > Met 128 k 17 
176 
64 f 11 
Gln > Lys 
177 
63 f 12 86 f 12 
178 
Ser > Pro 90 * 13 138 f 16 
Ser > Thr  78 k 2 
178 
31 + 4  
Ser > Arg 
179 Leu > Arg 
1 f 0.1 6 f l  
179 
3 f 0.1 
Leu > Gln 
30 f 0.8 
180 
1 8 f  1 
Arg > Lys 
26 f 9 
181 
3 f 0.8 
Ala > Asp 
l o *  1 
7 5 2  4 * 0.9 
181 
181 
Ala > Ser 84 f 10 49 f 3 
Ala > Thr 
182 
7 f 0.9 
Leu > Val 
34 f 6 
182 Leu > Phe 
91 f 24 116 f 9 
53 * 9 
182 
59 f 3 
Leu > Ile 39 k 3 
183 Arg > Gly 
101 f 16 
3 k 0.6 
183 Arg > Leu 
29 t 4 
7 + 2  
183 
15 f 5 
Arg>  Trp 
184 Gln > Pro 
2 f 0.1 18 f 2 
185 
32 & 3 
Met > Thr 
101 * 10 
28 k 7 33 f 4 
185 Met > Ile 98 f 8 69 k 11 
only nonconservative mutations  uch  as  changing  these 
charged residues  with noncharged residues result  in a  reduced 
activity,  but also replacement of  Arg”’ by Lys abolishes the 
activity completely. Substitution of the  noncharged Ser’78 and 
Led7’ with  nonconservative Arg residues  decreases IL-6  ac- 
tivity significantly. I t  seems  that  the nonconservative  replace- 
ments of amino acids is more  deleterious  for biological activity 
in the last 8 amino acids than for the more NH2-terminal 
amino  acids  that we studied.  IL-6  variants with  nonconser- 
vative mutations, L Y S ’ ~ ~   t o  Gln  and G l P  to Lys maintained 
more than  50% activity. We did not  find a variant with an 
amino acid substitution at position 171-177 that had an 
activity less than half of that of recombinant IL-6. This might 
be due to the kind of substitutions made, but more likely 
shows that  this region is functionally  less important  than  the 
last 8 amino acids. The Ser’77 to  Pro  mutation is important 
in  this  respect, because Pro is known to be able to disrupt 
helices. This  IL-6  variant  still  had a biological activity  com- 
parable with  wild-type. 
Besides the  importance of the charge of the side  groups of 
the various residues, the size of the side group seems to be 
important for proper  functioning of IL-6. This is particularly 
shown at position 181. The  replacement of the Ala”’ with  a 
hydrophilic Ser  that  has  about  the  same size side group as 
Ala, does not affect activity. In contrast, replacement by a 
hydrophilic Thr  that  has only one more methyl group than 
Ser reduces the  activity by 93%. 
We found only  two variants  that displayed  a  higher IL-6 
activity  on  the  human  hepatoma cell line as compared to wild- 
type IL-6. The substitutions were relatively  conservative, 
Phe”’ to Leu and Leu’75 to Met.  These IL-6 variants did not 
have a higher activity than human wild-type IL-6 on the 
mouse cell line 7TD1.  A  species pecificity of the  IL-6  variants 
was also noticed in  our previous studies with IL-6  mutants 
(21,26).  Most of those  variants, however, had a  higher  activity 
in the mouse cell line assays than in the human cell line 
assays. In the present study we also found that most IL-6 
variants displayed  a  higher activity  on mouse than on human 
cell lines. The residues G ~ u ’ ~ ~ ,  Phe’74, Led7‘, Arg’”’, Argl”, 
and GlnIa4 are conserved in  the COOH terminus in mouse, 
rat,  and  human IL-6.  Despite their  conservation  and  therefore 
apparent  importance, we only found a  significant  decrease of 
activity  in  the  variants with Arg”’ and ArglR3 replaced. Inter- 
estingly, these  two residues are also  conserved  in the COOH 
termini of human  G-CSF  andchicken myelomonocytic growth 
factor  that  both have  a  significant homology with  the COOH 
terminus of IL-6  (16,31) 
Receptor Binding of the IL-6 Variants-Binding assays were 
performed  using the  human myeloma cell line U-266. These 
cells have  a  high number of IL-6 receptors and  are therefore 
very suitable for IL-6  receptor  binding  analysis (13). U-266 
cells were incubated for 3  h at  4 “C with a constant concen- 
tration of radiolabeled  wild-type IL-6  and differing  concen- 
trations of unlabeled IL-6 or IL-6 variants for Scatchard 
analysis  and  the  competition  binding studies. Scatchard 
analysis of the specific binding of ‘2s1-IL-6 to U-266 cells 
revealed 19,850 binding sites/cell with a Kd value of 1.6 X 
10”’ M. The  binding  capacity of our  IL-6  variants was  ex- 
pressed as a percentage of our wild-type IL-6 by calculating 
the  quotient of the dissociation constants of wild-type IL-6/ 
variant  IL-6 (Fig. 2). Except  for four IL-6  variants with amino 
acid substitutions  that displayed normal biological activities, 
a t  least one IL-6 variant for every residue in the COOH 
terminus  that  had been substituted was tested for receptor 
binding capacity. 
The  results  are  summarized  in Fig. 2. In general, the binding 
studies were in  concordance with  the findings of the biological 
activity assays. However, one variant (Led7’ to Met) dis- 
played  a  3-fold  higher biological activity than receptor  binding 
capacity.  One variant (Phe17’ to Leu) with a  higher biological 
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FIG. 2. Percentage of residual receptor binding capacity of 
the IL-6 variants with  single amino acid substitutions in the 
COOH terminus expressed as a percentage of wild-type IL-6 
(open bars). The receptor binding  capacity was assayed by compe- 
tition binding  experiments  using the  human myeloma cell line U-266. 
The binding capacity of four mutants with a  normal biological activity 
was not determined (N .D. ) .  The biological activity of the  mutants 
assayed on a  human  hepatoma cell line HEP3B2 is shown in black 
bars. At  the top of the figure the amino acid sequence of the  last 15 
amino acids (171-185) of wild-type human IL-6 is shown. The single 
amino acid substitutions in the IL-6 variants are underlined. For 
details on the biological activity assays and the receptor binding 
experiments, see “Experimental  Procedures.” 
activity  on  the  human  hepatoma cell line compared  to wild- 
type  IL-6 also had  an  increased  affinity  to  the  IL-6 receptor. 
With  the exception of  Leu”’, the  variants  with  substitutions 
in the region between residues Ser’I8 and ArglS3 competed 
poorly against wild-type IL-6  for  the  IL-6 receptor. As indi- 
cated  in Fig. 2 most of these  variants  had less than 2%  receptor 
binding capacity compared to wild-type  IL-6. This  indicates 
that  the loss of biological activity  in  those  IL-6  variants  can 
be explained by an  inability  to  bind  to  the  IL-6 receptor and 
is not due to a  defective  signal transduction  upon  IL-6 recep- 
tor binding. It  can be deduced  from Fig. 2 that  the receptor 
binding region in  the COOH terminus of IL-6 is defined to 
the region between residues Ser17’ and ArgIs3 (Ser-Leu-Arg- 
Ala-X-Arg). 
DISCUSSION 
In order to  study  the  importance of individual  residues  in 
the COOH terminus of IL-6 for biological activity  and recep- 
tor binding we constructed a library of mutants  with single 
amino acid substitutions  in  the  last 15 amino acids of IL-6 
using  saturation mutagenesis. This  technique  is a very  effi- 
cient  tool  to make  several mutations  in a region of the  protein 
of interest (24, 32). In theory it is possible to  obtain every 
mutation  in  the region of interest by contaminating  the  phos- 
phoramidites with  a low amount of each of the  other  three 
during chemical synthesis of oligonucleotides covering the 
target region to be studied  (22). We were interested mostly in 
creating a library of single amino acid mutations  to  obtain 
information on the importance of each individual residue. 
After analyzing 201 clones by dideoxy sequencing, all 15 
amino acids had been replaced and a total of 63 unique 
mutants, of which 32 had single amino acid substitutions, 
were obtained.  The  random  mutagenesis procedure allowed 
us  to  study  the role of each  residue in  the COOH terminus of 
IL-6  in detail. 
We were interested  in  studying  the COOH terminus of IL- 
6  because  several reports suggested its  importance for biolog- 
ical activity. A number of deletion mutants  with  truncations 
at  the COOH terminus have a decreased biological activity 
(20-22), whereas truncations  up  to 28 residues at the  NH2 
terminus  did  not  alter biological activity  (21,33). Additionally, 
the COOH terminus  has recently  been  identified to be  impor- 
tant  in receptor binding for  various other  cytokines homolo- 
gous to  IL-6 (18, 19). Based on  computer modeling studies, 
Bazan proposed earlier that several cytokines and colony- 
stimulating  factors  have a common helical structure  at  the 
COOH  terminus  that  might be involved in receptor binding 
(16). This  amphipathical  a-helical  structure  is defined as  an 
a-helix  with opposing polar  and  nonpolar faces oriented along 
the long  axis of the helix (34).  A cartoon of the  amphipathical 
helix structure of the COOH terminus of IL-6  is shown in 
Fig. 3. As is  indicated, two distinct faces can be  seen at the 
surface of the helical wheel: a hydrophobic face mostly  con- 
sisting of Leu residues, and a highly hydrophilic face with 
mostly  charged  residues at  the surface. Amphipathical  struc- 
tures are found in a variety of proteins. Their functional 
properties are multiple and may include enhancement of 
receptor  binding probably  by  providing the  proper geometry 
for the ligand to  interact  with  the receptor  (35). 
A detailed  study  on  the  importance of an  a-helical  amphi- 
pathic  structure for  ligand-receptor interaction was reported 
by Cunningham and Wells (17). They studied the growth 
hormone-growth  hormone  binding  protein  interaction by al- 
anine  scanning mutagenesis. This  is of particular  interest for 
our study, because it is suggested, based on the secondary 
structure prediction of IL-6,  that  IL-6  has a  similar tertiary 
structure  as growth hormone, including the receptor binding 
FIG. 3. The last 18 residues in the COOH terminus of IL-6 
are illustrated as a helical wheel. The amphipathical nature of 
the  a-helix is shown in this figure. The hydrophilic face of the helix 
consists mostly of charged residues (hatched),  and  the hydrophobic 
face (gray) consists mainly of Leu residues. The residues labeled with 
an asterisk are  important for IL-6 receptor binding. 
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regions. This  tertiary  structure includes an  antiparallel  bundle 
of four a-helices (A-D) with a distinctive loop topology (36). 
In  growth hormone,  the  central  portion of the D-helix to  the 
COOH terminus was found to be important for receptor 
binding. Disruption of the  COOH-terminal  a-helical  structure 
in growth hormone by replacing  individual  residues with 
alanines resulted in a significant loss of growth hormone 
receptor binding and it was concluded that T Y ~ " ~  plays a 
central role. Based on the homology of IL-6 with growth 
hormone,  Bazan proposed t h a t   t h e   L y ~ ' ~ ~ - G l n ' ~ ~ - P h e ' ~ ~  region 
in  the COOH terminus of IL-6  and specifically the conserved 
aromatic residue in Phe'74 are important for IL-6 receptor 
binding (16, 31). In  our  study we made several mutations  in 
that  region and  found  that  the biological activity  and  receptor 
binding of those  IL-6  variants were not reduced. However, we 
identified  that  the  primary sequence Ser-Leu-Arg-Ala-X-Arg 
(positions 178-183) is  essential for IL-6  to  bind  to  its receptor. 
Mutations affecting the  amphipathical  nature of the helix in 
this region decreased biological activity  and  receptor  binding 
significantly. One mutation that actually keeps the amphi- 
pathic helix intact, Arg"' to Lys, nevertheless  resulted  in a 
loss of receptor binding, indicating a crucial role for this 
specific residue in  receptor binding. The  importance of the 
other Arg at  position  183 was already suggested  by the biolog- 
ical  inactivity of an  IL-6 deletion mutant  that lacked the  last 
three residues (22). We  show that  this residue is indeed  critical 
for biological activity, because several IL-6 variants with a 
substitution of this residue were inactive due to a loss of 
receptor binding. We suggest that Led7' is important for 
receptor binding,  whereas Leu''' does not seem to be impor- 
tant. However, our random mutagenesis procedure resulted 
only in nonconservative substitutions at position 179 and 
only hydrophobic residues at  position 182 as a substitution 
for  the leucines. Therefore we cannot exclude the possibility 
that  a  hydrophobic  residue at position 179 may be sufficient 
to keep the amphipathical nature of the helix intact and 
consequently  result  in  normal  IL-6  receptor binding. As can 
be seen in Fig. 3, the binding region (residues 178-183) is 
confined  to less than two turns  in  the helix and  the side chains 
project  to two different faces of the helix. This  is  in  contrast 
t o  growth hormone, where  all important residues  project to 
the same face of the helix. This  might  indicate  that  in  IL-6 
both faces of the  a-helix  are involved in  receptor binding. 
Recently, the  tertiary  structure of granulocyte  macrophage- 
colony-stimulating  factor  (GM-CSF) was  elucidated by x-ray 
crystallography  (37). It has a similar  bundle  structure of four 
helices as is determined for growth hormone and IL-4 (36, 
38), and predicted for IL-3,  IL-6,  erytropoietin,  and  G-CSF 
(16,19).  The receptors of all these  proteins belong to  the  same 
class I cytokine receptor  family (16, 39). Based  on  the  x-ray 
structure, two putative receptor binding  sites  are located in 
the  center of the  GM-CSF molecule. No involvement of the 
COOH  terminus  in  receptor  binding was indicated, which is 
in accordance  with earlier  structure-function  studies  on  GM- 
CSF (40). So although  proteins  such  as  IL-6, growth hormone 
and  GM-CSF  share  striking  similar  structural  patterns,  the 
location of their  receptor  binding  domains  seems  to be  differ- 
ent. All identified receptor  binding regions, however, share  an 
amphipathical helical structure necessary for a strong and 
specific interaction between  ligand and  receptor  (17,37, 41). 
The  interaction of IL-6 with its  receptor  starts by forming 
a complex with an  80-kDa  receptor  subunit followed by the 
binding of this complex to a second subunit, gp130, resulting 
in signal transduction (14). IL-6 by itself cannot bind to 
gp130, nor can the 80-kDa receptor (14). It is not known 
whether complex formation of IL-6  with  the  80-kDa  receptor 
results  in a conformational  change in IL-6  or  in  the  80-kDa 
receptor  that  makes a domain available on  one of them,  or 
that  they  mutually  form a domain  that recognizes gp130. This 
consecutive binding of a  ligand to  one  subunit, followed by 
the  binding of this complex to  an accessory receptor subunit 
is common in various  cytokines,  including  IL-2 and  IL-3 (42, 
43). Structure-function  analysis of mouse IL-2 indicated that 
two distinct regions in IL-2 bind to different IL-2 receptor 
subunits (42). Recently  it was  shown that two distinct regions 
in growth hormone bind in a similar way to two growth 
hormone  receptor molecules, resulting  in dimerization of the 
receptor by one growth hormone molecule (44). So for both 
these ligands  several domains  that  are  important for receptor 
binding have been identified. Because several other regions 
in  IL-6 besides the COOH terminus  are  important for biolog- 
ical activity, other receptor binding sites have also been 
predicted  for  IL-6,  including the region between  residues 29 
through 34 and residues  153 trough 162 (33, 45). These 
different regions might be involved in  creating  the pitope on 
IL-6  that  binds  to gp130 after  interaction of IL-6 with the 80- 
kDa receptor. 
For  our  receptor  binding  studies we used the  human mye- 
loma cell line U-266,  which has a  high number of IL-6 recep- 
tors (14). Although the results of the activity assay are in 
agreement with the results of the binding assays for most 
variants, one IL-6 variant had a  3-fold  higher biological 
activity  than  receptor  binding capacity. This may be explained 
by the  fact  that we used  a human  hepatoma cell line  for the 
determination of the biological activity  and a human myeloma 
cell line for receptor binding. The difference in the relative 
amount of the two IL-6 receptor subunits  on  these two cell 
lines  may  influence the  binding capacity of the  IL-6  variants 
and  result  in a tissue specific variation. Because the  results 
of the  activity  assay were in  agreement with the binding  assay 
for  all the  other  variants, we feel that  our  results  indicate  that 
a change in biological activity of our  IL-6  variants compared 
to wild-type IL-6  can be explained by a change  in receptor 
binding. Clearly, the biologically inactive variants that we 
constructed by substituting  amino acids in  the COOH termi- 
nus of IL-6 are not binding to the IL-6 receptor. Future 
structure-function studies on the different regions of IL-6 
that  are suggested to be involved in receptor  binding and  the 
use of soluble receptor subunits for binding assays might 
provide  more insight  in  the  interaction of IL-6 with both  the 
receptor  subunits.  This  is especially important for the devel- 
opment of IL-6  antagonists  and agonists. 
In  recent  years,  naturally occurring or engineered variants 
of several cytokines  such  as  IL-1  and  IL-2 have been  identified 
that  have a  reduced or defective biological activity, but  still 
maintain  receptor  binding (46,47) These  variants have  been 
used as  antagonists for cytokine activity and have  shown very 
useful in animal disease models (46). Antagonists of IL-6 
might  also be of therapeutic use in several  disease states in 
which IL-6 is involved in  the pathogenesis, such  as multiple 
myeloma, proliferative glomerulonephritis, and sepsis (48- 
50). Because IL-6 can act as a potent growth factor for 
myeloma  cells it  is considered of main pathogenetic impor- 
tance  in multiple  myeloma (11,51).  Studies using neutralizing 
murine monoclonal antibodies  against  IL-6 have  shown prom- 
ising results in patients with end-stage multiple myeloma 
(51). The  immunization  encountered  during  treatment with 
monoclonal antibodies, as has been reported in several pa- 
tients, stresses the need of a nonantigenic IL-6 antagonist 
(52). So far we have not identified antagonists for  IL-6,  nor 
have  others  performing  structure  function  experiments.  In all 
the  IL-6  variants  that  have been constructed  and  appropri- 
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ately  tested, the decrease of the biological activity was paral- 
leled by a decreased receptor binding (19, 40). In  this study 
we have identified a  potential agonist for IL-6 activity; the 
IL-6 variant with Phe17' replaced by Leu had a higher biolog- 
ical activity on  a  human  hepatoma cell line compared to wild- 
type IL-6 that was associated with an increased binding 
capacity of this variant to the IL-6 receptor on a human 
myeloma  cell  line. An agonist of IL-6 might be  of therapeutic 
value as an inducer of platelet production in patients with 
thrombopenia, in combination with other cytokines useful for 
patients undergoing bone marrow transplantation or used as 
an inhibitor of cell growth in patients with myeloid leukemia 
(10,531. 
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